ClinicalTrials.gg
CompletedNCT02518451Updated Aug 7, 2015

Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg

An interventional study of Valsartan 160 mg film-coated caplets (test formulation) and Valsartan 160 mg film-coated caplets (reference formulation) in Healthy, sponsored by Dexa Medica Group. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-07.

Sponsored by Dexa Medica Group · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This was a randomized, single-blind, two-period, two sequence cross-over study under fasting condition, with a one-week wash-out period, to compare the pharmacokinetic profiles and bioavailability of two formulations (the test and reference) of valsartan 160 mg film-coated caplets.

Read the detailed description

In the first period, subjects received either the test formulation (160 mg valsartan film-coated caplets produced by PT Dexa Medica, Palembang, Indonesia) once daily, or the innovator film-coated tablets (Diovan® 160, Novartis Farmaceutica S.A., Barbera del Valles, Spain for Novartis Pharma AG, Basel, Switzerland) once daily as the reference formulation. In the subsequent period, after a one-week wash-out period, they received the alternate drug.

At the night before starting the study, subjects were instructed to fast from any food and drink but mineral water for 9 hours before the drug administration. In the morning after, at the dosing day, each of the 48 subjects then swallowed (without chewing) one dose of valsartan 160 mg of the test formulation or of the reference formulation, with 200 mL of water. As much as 5 mL of blood samples for drug assay were drawn again from each subject, at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 9, 12, 16, 24, 36, and 48 hours after dosing.

The concentrations of valsartan in plasma were assayed using a validated high performance liquid chromatography with fluorescence detector (HPLC-FL) method. Pharmacokinetic parameters, including the area under the concentration-versus-time curve (AUC) from time zero to the time of last quatifiable concentration (48 hours after dosing) (AUC-t), AUC from time zero extrapolated to infinity (AUC-inf), maximum concentration (Cmax), time to reach the maximum concentration (tmax), and half-life (t1/2), were assessed in this study.

02

Conditions studied

  • Healthy

Keywords

  • antihypertensive
  • bioequivalence
  • formulation
  • pharmakokinetic
  • valsartan
  • subjects
  • Fasting conditions
03

In context

Lead sponsor

Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects with absence of significant disease or abnormal laboratory values on laboratory evaluation, medical history or physical examination during screening.
  2. Aged 18 - 55 years inclusive
  3. Preferably non-smokers or smoke less than 10 cigarettes per day.
  4. Able to participate, communicate well with the investigators and willing to provide written to participate in the study.
  5. within 18 to 25 kg/m2.
  6. Vital signs (after 10 minutes rest) must be within the following ranges:

    • Systolic blood pressure : 110 - 120 mm Hg
    • Diastolic blood pressure : 70 - 80 mm Hg
    • Pulse rate : 60 - 90 bpm

Exclusion criteria

Exclusion Criteria:

  1. Personal/family history of allergy or or to valsartan or allied drugs.
  2. Pregnant or lactating women (urinary pregnancy test will be applied to women subjects just before taking the study drug).
  3. Any major illness in the past 90 days or ongoing chronic medical illness e.g. congestive heart failure, hepatitis, hypotensive episodes, hyperglycemia, etc.
  4. Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver function test (, alkaline phosphatase, total >= 1.5 ), renal function test (serum creatinine concentration > 1.4 mg/dL), etc.
  5. Positive surface antigen (HBsAg), anti-, or anti-.
  6. Clinically significant haematology abnormalities.
  7. Clinically significant (ECG) abnormalities.
  8. Any surgical or medical condition (present or history) which might significantly alter the absorption, distribution, metabolism or excretion of the study drug, e.g. gastrointestinal diseases including gastric or duodenal ulcers or history of gastric surgery.
  9. Past history of anaphylaxis or angioedema.
  10. History of drug or alcohol abuse within 12 months prior to screening for this study.
  11. Participation in any clinical trial within the past 90 days calculated from the last visit.
  12. History of any bleeding or coagulative disorders.
  13. History of difficulty with donating blood or difficulty in accessibility of veins in left or right arm.
  14. A donation or loss of 300 mL (or more) of blood within 3 months before this study's first dosing day.
  15. Intake of any prescription or non-prescription drug, food supplement or herbal medicine within 14 days of this study's first dosing day.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    (Test) Group I

    Valsartan 160 mg film-coated caplets of PT Dexa Medica

    Drug: Valsartan 160 mg film-coated caplets (test formulation)

  • Active comparator
    (Reference) Group II

    Valsartan 160 mg film-coated caplets (Diovan® 160)

    Drug: Valsartan 160 mg film-coated caplets (reference formulation)

Interventions

06

What researchers measure

Primary outcomes

  1. AUCt

    Area under the curve of plasma concentrations versus time from time zero to the time of last observed quantifiable concentration was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)

    Time frame: 48 hours

  2. AUCinf

    Area under the curve of plasma concentrations versus time from time zero to infinity was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)

    Time frame: 48 hours

  3. Cmax

    The maximum (peak) plasma concentration was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)

    Time frame: 48 hours

Secondary outcomes

  1. Tmax

    The time of peak plasma concentration was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)

    Time frame: 48 hours

  2. T1/2

    The elimination half-life was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)

    Time frame: 48 hours

Other outcomes

  1. Adverse events

    The presence of adverse events will be observed, reported and sufficiently handled during subjects' participation in the study (1 month).

    Time frame: 1 months

07

Study locations

1 site
  • PT Equilab International
    Jakarta, 12430, Indonesia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Oct 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2015
First posted
Aug 7, 2015
Start
Jun 2013
Primary completionActual
Oct 2013
CompletionActual
Mar 2014
Last update
Aug 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02518451
Lead sponsor
Dexa Medica Group
Responsible party
Sponsor
First posted
Aug 7, 2015
Start date
Jun 2013
Primary completion
Oct 2013
Completion
Mar 2014
Last update
Aug 7, 2015

Study contacts

Effi Setiawati, MSc
study director · PT Equilab International

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion